tiprankstipranks
Duality Biotherapeutics, Inc. (HK:9606)
:9606
Hong Kong Market
9606
Duality Biotherapeutics, Inc.
RESEARCH TOOLSreports
Want to see HK:9606 full AI Analyst Report?

Duality Biotherapeutics, Inc. (9606) Ratios

4 Followers

Duality Biotherapeutics, Inc. Ratios

HK:9606's free cash flow for Q2 2025 was ¥0.48. For the 2025 fiscal year, HK:9606's free cash flow was decreased by ¥ and operating cash flow was ¥0.10. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
 3.65 3.61 0.49 0.52
Quick Ratio
 3.65 3.61 0.49 0.52
Cash Ratio
 1.26 1.26 0.31 0.44
Solvency Ratio
 -1.74 -1.72 -0.25 -0.13
Operating Cash Flow Ratio
 0.81 0.18 0.07 0.32
Short-Term Operating Cash Flow Coverage
 6.06 1.38 0.00 0.00
Net Current Asset Value
¥ 2.37B¥ 2.33B¥ -2.20B¥ -1.29B
Leverage Ratios
Debt-to-Assets Ratio
 0.04 0.04 <0.01 <0.01
Debt-to-Equity Ratio
 0.06 0.06 >-0.01 >-0.01
Debt-to-Capital Ratio
 0.06 0.06 >-0.01 >-0.01
Long-Term Debt-to-Capital Ratio
 0.00 0.00 0.00 0.00
Financial Leverage Ratio
 1.60 1.60 -1.03 -1.33
Debt Service Coverage Ratio
 -2.54 -2.84 -4.17K -1.87K
Interest Coverage Ratio
 -144.20 -353.16 -755.97 4.16K
Debt to Market Cap
 <0.01 <0.01 0.00 0.00
Interest Debt Per Share
 3.59 2.32 0.07 0.07
Net Debt to EBITDA
 3.33 2.91 1.20 5.71
Profitability Margins
Gross Profit Margin
41.83%31.15%40.42%76.06%
EBIT Margin
-21.17%-23.08%-52.25%-11.31%
EBITDA Margin
-20.70%-22.41%-51.84%-11.03%
Operating Profit Margin
-0.51%-23.08%-9.74%43.74%
Pretax Profit Margin
-149.43%-140.13%-52.26%-11.32%
Net Profit Margin
-149.74%-140.13%-54.11%-20.01%
Continuous Operations Profit Margin
-149.74%-140.13%-54.11%-20.01%
Net Income Per EBT
100.21%100.00%103.54%176.77%
EBT Per EBIT
29019.01%607.23%536.82%-25.88%
Return on Assets (ROA)
-65.71%-64.90%-50.25%-23.84%
Return on Equity (ROE)
-164.22%-104.12%51.95%31.81%
Return on Capital Employed (ROCE)
-0.31%-14.65%10.61%-73.62%
Return on Invested Capital (ROIC)
-0.29%-13.93%10.63%-73.82%
Return on Tangible Assets
-65.77%-64.97%-51.39%-24.73%
Earnings Yield
-27.59%-14.48%-6.56%-2.31%
Efficiency Ratios
Receivables Turnover
 5.91 6.24 5.12 17.72
Payables Turnover
 1.30 1.63 1.72 1.82
Inventory Turnover
 0.00 0.00 0.00 0.00
Fixed Asset Turnover
 59.57 62.88 104.40 100.60
Asset Turnover
 0.44 0.46 0.93 1.19
Working Capital Turnover Ratio
 0.57 4.59 -1.22 -1.74
Cash Conversion Cycle
 -218.10 -165.51 -140.45 -179.81
Days of Sales Outstanding
 61.78 58.51 71.27 20.60
Days of Inventory Outstanding
 0.00 0.00 0.00 0.00
Days of Payables Outstanding
 279.88 224.02 211.73 200.41
Operating Cycle
 61.78 58.51 71.27 20.60
Cash Flow Ratios
Operating Cash Flow Per Share
 20.50 2.99 3.44 9.81
Free Cash Flow Per Share
 20.26 2.78 3.06 9.38
CapEx Per Share
 0.24 0.21 0.37 0.43
Free Cash Flow to Operating Cash Flow
 0.99 0.93 0.89 0.96
Dividend Paid and CapEx Coverage Ratio
 85.00 14.18 9.17 22.74
Capital Expenditure Coverage Ratio
 85.00 14.18 9.17 22.74
Operating Cash Flow Coverage Ratio
 5.71 1.30 54.03 153.50
Operating Cash Flow to Sales Ratio
 0.50 0.11 0.15 0.46
Free Cash Flow Yield
4.25%1.04%1.59%5.05%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -3.63 -6.90 -15.25 -43.22
Price-to-Sales (P/S) Ratio
 11.64 9.67 8.25 8.65
Price-to-Book (P/B) Ratio
 3.82 7.19 -7.92 -13.75
Price-to-Free Cash Flow (P/FCF) Ratio
 23.52 96.49 62.90 19.80
Price-to-Operating Cash Flow Ratio
 10.84 89.69 56.04 18.93
Price-to-Earnings Growth (PEG) Ratio
 0.04 -0.03 -0.08 5.74
Price-to-Fair Value
 3.82 7.19 -7.92 -13.75
Enterprise Value Multiple
 -52.88 -40.26 -14.72 -72.69
Enterprise Value
 18.70B 16.27B 14.81B 14.32B
EV to EBITDA
 -52.88 -40.26 -14.72 -72.69
EV to Sales
 10.95 9.02 7.63 8.02
EV to Free Cash Flow
 22.13 89.99 58.17 18.35
EV to Operating Cash Flow
 21.87 83.64 51.83 17.55
Tangible Book Value Per Share
 58.10 37.20 -24.86 -14.16
Shareholders’ Equity Per Share
 58.19 37.26 -24.31 -13.51
Tax and Other Ratios
Effective Tax Rate
 >-0.01 0.00 -0.04 -0.77
Revenue Per Share
 40.96 27.68 23.34 21.48
Net Income Per Share
 -61.33 -38.79 -12.63 -4.30
Tax Burden
 1.00 1.00 1.04 1.77
Interest Burden
 7.06 6.07 1.00 1.00
Research & Development to Revenue
 0.34 0.45 0.43 0.31
SG&A to Revenue
 0.08 0.09 0.02 0.02
Stock-Based Compensation to Revenue
 0.07 0.09 0.10 0.01
Income Quality
 -0.34 -0.07 -0.28 -4.04
Currency in CNY